March 16, 2016

MacroGenics Announces Five Posters at AACR Annual Meeting 2016

ROCKVILLE, Maryland, March 16, 2016 (GLOBE NEWSWIRE) --

MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and infectious diseases, today announced that it will present five posters at the 2016 American Association for Cancer Research (AACR) Annual Meeting in New Orleans, Louisiana. Four of the five posters refer to programs that are based on MacroGenics' Dual-Affinity Re-Targeting (DART®) bispecific technology. The five posters are:

Title: Evaluation of EphA2 as a therapeutic target for redirected T-cell killing by DART® bispecific molecules

Time: Sunday, April 17, 2016, 1:00 pm - 5:00 pm CDT

Location: Poster Section 27

Poster Board Number: 14

Session Title: Therapeutic Antibodies

Abstract Number: 583

Title: Development of a humanized ROR1 x CD3 bispecific DART® molecule for the treatment of solid and liquid tumors

Time: Monday, April 18, 2016, 8:00 am - 12:00 pm CDT

Location: Poster Section 25

Poster Board Number: 20

Session Title: Immune Modulating Agents and Therapeutic Antibodies

Abstract Number: 1489

Title: Development of an IL13Ralpha2 x CD3 bispecific DART® protein for redirected T-cell killing of solid tumors

Time: Monday, April 18, 2016, 8:00 am - 12:00 pm CDT

Location: Poster Section 25

Poster Board Number: 29

Session Title: Immune Modulating Agents and Therapeutic Antibodies

Abstract Number: 1498

Title: Anti-B7-H3 antibody-drug conjugates as potential therapeutics for solid cancer

Time: Monday, April 18, 2016, 8:00 am - 12:00 pm CDT

Location: Poster Section 15

Poster Board Number: 10

Session Title: Growth Factor Receptors and Surface Antigens as Therapeutic Targets

Abstract Number: 1201

Title: MGD013, a bispecific PD-1 x LAG-3 Dual-Affinity Re-Targeting (DART®) protein with T-cell immunomodulatory activity for cancer treatment

Time: Tuesday, April 19, 2016, 8:00 am - 12:00 pm CDT

Location: Poster Section 25

Poster Board Number: 14

Session Title: Immune Checkpoints 2

Abstract Number: 3217

About the DART Platform

MacroGenics' Dual-Affinity Re-Targeting, or DART, platform enables the creation of potential medicines comprised of a single antibody-like molecule designed to simultaneously bind to two target antigens. The Company has created over 100 DART molecules with potential therapeutic applications spanning treatment of cancer, autoimmune disorders and infectious diseases. DART molecules can be tailored for either short or prolonged pharmacokinetics and have demonstrated good stability and attractive manufacturability. The versatility of the DART platform allows for the exploitation of a variety of intended mechanisms of action. Today, six DART product candidates, including those licensed to collaboration partners, are in or near clinical studies, with several additional product candidates in pre-clinical development.

About MacroGenics, Inc.

MacroGenics is a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and infectious diseases. The company generates its pipeline of product candidates from its proprietary suite of next-generation antibody-based technology platforms. The combination of MacroGenics' technology platforms and protein engineering expertise has allowed the Company to generate promising product candidates and enter into several strategic collaborations with global pharmaceutical and biotechnology companies. For more information, please see the Company's website at www.macrogenics.com. DART, MacroGenics and the MacroGenics logo are trademarks or registered trademarks of MacroGenics, Inc.

Cautionary Note on Forward-Looking Statements

Any statements in this press release about future expectations, plans and prospects for the Company, including statements about the Company's strategy, future operations, clinical development of the Company's therapeutic candidates, milestone or opt-in payments from the Company's collaborators, the Company's anticipated milestones and future expectations and plans and prospects for the Company and other statements containing the words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various

important factors, including: the uncertainties inherent in the initiation and enrollment of future clinical trials, expectations of expanding ongoing clinical trials, availability and timing of data from ongoing clinical trials, expectations for regulatory approvals, other matters that could affect the availability or commercial potential of the Company's product candidates and other risk factors described in the Company's filings with the Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent the Company's views as of the date hereof. The Company anticipates that subsequent events and developments will cause the Company's views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date hereof.

CONTACT:

Jim Karrels, Senior Vice President, CFO
MacroGenics, Inc.
1-301-251-5172, info@macrogenics.com

Karen Sharma, Senior Vice President
MacDougall Biomedical Communications
1-781-235-3060, ksharma@macbiocom.com